Discovery and Development of Anti-HIV Therapeutic Agents: Progress Towards Improved HIV Medication

被引:67
作者
Maeda, Kenji [1 ]
Das, Debananda [2 ]
Kobayakawa, Takuya [3 ]
Tamamura, Hirokazu [4 ]
Takeuchi, Hiroaki [4 ]
机构
[1] Natl Ctr Global Hlth & Med NCGM, Res Inst, Tokyo 1628655, Japan
[2] NCI, Expt Retrovirol Sect, HIV & AIDS Malignancy Branch, NIH, Bethesda, MD 20892 USA
[3] Tokyo Med & Dent Univ, Inst Biomat & Bioengn, Tokyo 1010062, Japan
[4] Tokyo Med & Dent Univ, Dept Mol Virol, Tokyo 1138519, Japan
关键词
HIV; AIDS; Combination antiretroviral therapy; Reverse transcriptase inhibitors; Protease inhibitors; Integrase inhibitors; IMMUNODEFICIENCY-VIRUS TYPE-1; REVERSE-TRANSCRIPTASE INHIBITORS; SMALL-MOLECULE INHIBITORS; RESISTANCE-ASSOCIATED MUTATIONS; ACTIVE ANTIRETROVIRAL THERAPY; HISTONE DEACETYLASE INHIBITOR; STRAND TRANSFER INHIBITORS; CHEMOKINE RECEPTOR CCR5; SYNTHETIC C34 TRIMER; IN-VITRO SELECTION;
D O I
10.2174/1568026619666190712204603
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The history of the human immunodeficiency virus (HIV)/AIDS therapy, which spans over 30 years, is one of the most dramatic stories of science and medicine leading to the treatment of a disease. Since the advent of the first AIDS drug, AZT or zidovudine, a number of agents acting on different drug targets, such as HIV enzymes (e.g. reverse transcriptase, protease, and integrase) and host cell factors critical for HIV infection (e.g. CD4 and CCR5), have been added to our armamentarium to combat HIV/AIDS. In this review article, we first discuss the history of the development of anti-HIV drugs, during which several problems such as drug-induced side effects and the emergence of drug-resistant viruses became apparent and had to be overcome. Nowadays, the success of Combination Antiretroviral Therapy (cART), combined with recently-developed powerful but nonetheless less toxic drugs has transformed HIV/AIDS from an inevitably fatal disease into a manageable chronic infection. However, even with such potent cART, it is impossible to eradicate HIV because none of the currently available HIV drugs are effective in eliminating occult "dormant" HIV cell reservoirs. A number of novel unique treatment approaches that should drastically improve the quality of life (QOL) of patients or might actually be able to eliminate HIV altogether have also been discussed later in the review.
引用
收藏
页码:1621 / 1649
页数:29
相关论文
共 241 条
  • [1] Impact of Primary Elvitegravir Resistance-Associated Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication Fitness
    Abram, Michael E.
    Hluhanich, Rebecca M.
    Goodman, Derrick D.
    Andreatta, Kristen N.
    Margot, Nicolas A.
    Ye, Linda
    Niedziela-Majka, Anita
    Barnes, Tiffany L.
    Novikov, Nikolai
    Chen, Xiaowu
    Svarovskaia, Evguenia S.
    McColl, Damian J.
    White, Kirsten L.
    Miller, Michael D.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (06) : 2654 - 2663
  • [2] CC CKRS: A RANTES, MIP-1 alpha, MIP-1 beta receptor as a fusion cofactor for macrophage-tropic HIV-1
    Alkhatib, G
    Combadiere, C
    Broder, CC
    Feng, Y
    Kennedy, PE
    Murphy, PM
    Berger, EA
    [J]. SCIENCE, 1996, 272 (5270) : 1955 - 1958
  • [3] HIV-1 uncoating: connection to nuclear entry and regulation by host proteins
    Ambrose, Zandrea
    Aiken, Christopher
    [J]. VIROLOGY, 2014, 454 : 371 - 379
  • [4] Ankrom W., 2016, ANN C RETR OPP INF C
  • [5] [Anonymous], 90 90 90 AMB TREATM
  • [6] Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
    Archin, N. M.
    Liberty, A. L.
    Kashuba, A. D.
    Choudhary, S. K.
    Kuruc, J. D.
    Crooks, A. M.
    Parker, D. C.
    Anderson, E. M.
    Kearney, M. F.
    Strain, M. C.
    Richman, D. D.
    Hudgens, M. G.
    Bosch, R. J.
    Coffin, J. M.
    Eron, J. J.
    Hazuda, D. J.
    Margolis, D. M.
    [J]. NATURE, 2012, 487 (7408) : 482 - U1650
  • [7] Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT):: Increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase
    Arion, D
    Kaushik, N
    McCormick, S
    Borkow, G
    Parniak, MA
    [J]. BIOCHEMISTRY, 1998, 37 (45) : 15908 - 15917
  • [8] HIV-1 Antiretroviral Drug Therapy
    Arts, Eric J.
    Hazuda, Daria J.
    [J]. COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2012, 2 (04):
  • [9] CD4+ T-Cell Restoration After 48 Weeks in the Maraviroc Treatment-Experienced Trials MOTIVATE 1 and 2
    Asmuth, David M.
    Goodrich, James
    Cooper, David A.
    Haubrich, Richard
    Rajicic, Natasa
    Hirschel, Bernard
    Mayer, Howard
    Valdez, Hernan
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 54 (04) : 394 - 397
  • [10] Positive effects of combined antiretroviral therapy on CD4(+) T cell homeostasis and function in advanced HIV disease
    Autran, B
    Carcelain, G
    Li, TS
    Blanc, C
    Mathez, D
    Tubiana, R
    Katlama, C
    Debre, P
    Leibowitch, J
    [J]. SCIENCE, 1997, 277 (5322) : 112 - 116